X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Experimental Hematology & Oncology

期刊標題檢索 EXP HEMATOL ONC 最新評論: After being rejected by editor Liu Delong, JHO switched to EHO and ... (2025-02-23)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Experimental Hematology & Oncology]您好,您是該頁面的第 23150 位訪客。

期刊簡介
期刊名稱Experimental Hematology & Oncology Experimental Hematology & Oncology
LetPub Score
6.0
50 ratings
Rate

Reputation
7.2

Influence
4.9

Speed
7.1

期刊簡稱EXP HEMATOL ONCOL
ISSN2162-3619
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
12.602.3841.583
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q142 / 404
Category: Medicine
Subcategory: Hematology
Q117 / 137
Category: Medicine
Subcategory: Cancer Research
Q135 / 230

自引率 (2023-2024)6.40%自引率趨勢
掲載範囲
Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with "negative" or preliminary results and basic science studies with provocative findings.
官方網站https://www.springer.com/journal/40164
在線稿件提交https://www.editorialmanager.com/EXHO
開放訪問Yes
出版商BioMed Central
主題領域Medicine
出版國/地區ENGLAND
發行頻率
創刊年2012
每年文章數71每年文章數趨勢
黃金OA百分比100.00%
OA Related Info
APC: Yes( GBP2490; USD3190; EUR2790; )
APC waiver:Check Notes
Other charges: No
Keywords: haematology、oncology
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
HEMATOLOGYSCIEQ110/97
ONCOLOGYSCIEQ132/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-3619%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 6 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Experimental Hematology & Oncology】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Nature CancerH-index: 0

    CiteScore: 31.10
    JAMA OncologyH-index: 41

    CiteScore: 37.50
    JAMA OncologyH-index: 61

    CiteScore: 37.50
    Trends in CancerH-index: 0

    CiteScore: 28.50
    Liver CancerH-index: 25

    CiteScore: 20.80
    ESMO OpenH-index: 0

    CiteScore: 11.70
    Cancer Biology & MedicineH-index: 29

    CiteScore: 9.80
    Annual Review of Cancer BiologyH-index: 0

    CiteScore: 14.50
    CancersH-index: 53

    CiteScore: 8.00
    Translational Lung Cancer ResearchH-index: 0

    CiteScore: 7.20
    學科內最受檢索的期刊 頁面查看次數
    Cancers238660
    OncoTargets and Therapy217976
    Cancer Management and Research159983
    Journal of Oncology121981
    Cancer Biology & Medicine59367
    Molecular Therapy-Oncolytics44568
    JAMA Oncology37750
    Liver Cancer35151
    Nature Cancer34089
    Translational Lung Cancer Research30374
  •  

    Experimental Hematology & Oncology Experimental Hematology & Oncology
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Experimental Hematology & Oncology] 的評論撰寫評論
作者: PanchoZ


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2025-02-23 10:38:52 評論於
After being rejected by editor Liu Delong, JHO switched to EHO and submitted to a collection that happened to be available at that time. However, the article remained stagnant in the hands of the responsible editor of that collection for over a month. After sending an inquiry letter, the article finally landed in the hands of editor Liu Delong, who showed extremely high efficiency. Kudos to Liu for his quick response!
(0) 讚! | PanchoZ

作者: PanchoZ


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2025-02-23 10:35:30 評論於
Here are the submission deadlines for JHO and EHO:
JHO submitted first.
(0) 讚! | PanchoZ

作者: PanchoZ


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2025-02-23 10:33:11 評論於
Just received a paper, which was transferred to me after being rejected by the sister journal JHO for review. After the transfer, it was not reviewed, but I was asked to supplement according to the dozens of opinions given by the 4 reviewers of JHO. After working hard to complete the supplement, it was sent back and another reviewer was found, who provided some additional opinions. After completing another round of supplements, it was sent back and accepted after a minor formatting revision. Overall, the quality of articles in this journal is uneven, with some good quality articles, but also some obvious cases of favoritism leading to poor reputation of the journal. The journal's speed is relatively fast, and in a rush to graduate, I agreed to transfer to EHO. To be honest, it was a bit of a loss to follow the dozens of review opinions from JHO and publish in EHO, but looking at the rising impact factor of the sister journal JHO, it is likely that this journal will also rise. Hopefully the journal will continue to improve, while publishing fewer low-quality articles!
(0) 讚! | PanchoZ

作者: 萧赢


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2022-09-02 20:48:47 評論於
5-18 Submission
6-3 Resubmission after format modification
6-8 Reviewer's comment
8-9 Revision
8-12 Resubmission
8-13 Reviewer's comment
8-26 Major revision
8-27 Resubmission
8-29 Invite another reviewer
8-30 Reviewer's comment
8-30 Minor revision
8-31 Resubmission again
9-2 Acceptance
(0) 讚! | 萧赢

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Experimental Hematology & Oncology] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*